DK3419624T3 - Fremgangsmåder til anvendelse af fxr-agonister - Google Patents
Fremgangsmåder til anvendelse af fxr-agonister Download PDFInfo
- Publication number
- DK3419624T3 DK3419624T3 DK17708341.7T DK17708341T DK3419624T3 DK 3419624 T3 DK3419624 T3 DK 3419624T3 DK 17708341 T DK17708341 T DK 17708341T DK 3419624 T3 DK3419624 T3 DK 3419624T3
- Authority
- DK
- Denmark
- Prior art keywords
- procedures
- fxr agonists
- fxr
- agonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662298113P | 2016-02-22 | 2016-02-22 | |
| PCT/IB2017/050962 WO2017145040A1 (en) | 2016-02-22 | 2017-02-20 | Methods for using fxr agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3419624T3 true DK3419624T3 (da) | 2021-04-19 |
Family
ID=58192341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17708341.7T DK3419624T3 (da) | 2016-02-22 | 2017-02-20 | Fremgangsmåder til anvendelse af fxr-agonister |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11110083B2 (da) |
| EP (2) | EP3419624B1 (da) |
| JP (1) | JP6941109B2 (da) |
| KR (1) | KR20180115700A (da) |
| CN (1) | CN108697703A (da) |
| AU (1) | AU2017223154B2 (da) |
| CA (1) | CA3014733A1 (da) |
| DK (1) | DK3419624T3 (da) |
| ES (1) | ES2862194T3 (da) |
| HK (1) | HK1257649A1 (da) |
| HU (1) | HUE053743T2 (da) |
| IL (1) | IL261036A (da) |
| PL (1) | PL3419624T3 (da) |
| PT (1) | PT3419624T (da) |
| RU (1) | RU2737324C2 (da) |
| SI (1) | SI3419624T1 (da) |
| TW (1) | TW201733583A (da) |
| WO (1) | WO2017145040A1 (da) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE054819T2 (hu) | 2016-02-22 | 2021-10-28 | Novartis Ag | Eljárások FXR agonista alkalmazására |
| ES2902404T3 (es) | 2016-02-22 | 2022-03-28 | Novartis Ag | Métodos para utilizar agonistas de fxr. |
| JOP20190040A1 (ar) * | 2016-09-14 | 2019-03-10 | Novartis Ag | توليفة من ناهضات fxr |
| CA3039283A1 (en) * | 2016-10-05 | 2018-04-12 | Novartis Ag | Combination compositions comprising fxr agonists for treating or preventing a fibrotic,cirrhotic disease or disorder |
| CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| AR114930A1 (es) | 2017-09-12 | 2020-11-11 | Novartis Ag | Composición farmacéutica |
| WO2019053582A1 (en) * | 2017-09-13 | 2019-03-21 | Novartis Ag | COMBINATIONS HAVING FXR AGONISTS |
| ES2944657T3 (es) | 2017-11-01 | 2023-06-23 | Bristol Myers Squibb Co | Compuestos de alqueno como moduladores del receptor farnesoide X |
| BR112020008157A2 (pt) | 2017-11-01 | 2020-10-06 | Bristol-Myers Squibb Company | compostos espirocíclicos como moduladores do receptor farnesoide x |
| CN111278817B (zh) | 2017-11-01 | 2023-05-16 | 百时美施贵宝公司 | 作为法尼醇x受体调节剂的多环化合物 |
| EP3704113B1 (en) | 2017-11-01 | 2023-10-11 | Bristol-Myers Squibb Company | Bridged bicyclic compounds as farnesoid x receptor modulators |
| WO2019089665A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid x receptor modulators |
| EP3716977A1 (en) * | 2017-11-30 | 2020-10-07 | Novartis AG | Fxr agonists for the treatment of liver diseases |
| EP3730491B1 (en) | 2017-12-22 | 2022-07-20 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Isoxazole derivative, preparation method therefor, and use thereof |
| CA3112414A1 (en) * | 2018-09-18 | 2020-03-26 | Metacrine, Inc. | Farnesoid x receptor agonists for the treatment of disease |
| WO2020168152A2 (en) | 2019-02-15 | 2020-08-20 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid x receptor modulators |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| EP3999101A1 (en) | 2019-07-18 | 2022-05-25 | ENYO Pharma | Method for decreasing adverse-effects of interferon |
| WO2021009331A1 (en) * | 2019-07-18 | 2021-01-21 | Enyo Pharma | Improved treatment using eyp001 |
| JP2022550312A (ja) * | 2019-09-30 | 2022-12-01 | ノバルティス アーゲー | Ｆｘｒアゴニストの使用を含む処置 |
| JP2023510274A (ja) | 2020-01-15 | 2023-03-13 | アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） | Ｄ型肝炎ウイルスによる感染を処置するためのｆｘｒアゴニストの使用 |
| WO2022152770A1 (en) | 2021-01-14 | 2022-07-21 | Enyo Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| CN114903905B (zh) * | 2021-02-09 | 2024-04-02 | 中国人民解放军陆军军医大学第二附属医院 | 甘氨脱氧胆酸在制备治疗肝内胆汁淤积药物中的应用及其药物组合物 |
| TW202308629A (zh) | 2021-04-28 | 2023-03-01 | 法商Ｅｎｙｏ製藥公司 | 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003290700A1 (en) * | 2002-11-22 | 2004-06-18 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| CU24152B1 (es) | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| HUE054819T2 (hu) | 2016-02-22 | 2021-10-28 | Novartis Ag | Eljárások FXR agonista alkalmazására |
| ES2902404T3 (es) | 2016-02-22 | 2022-03-28 | Novartis Ag | Métodos para utilizar agonistas de fxr. |
-
2017
- 2017-02-20 KR KR1020187023975A patent/KR20180115700A/ko unknown
- 2017-02-20 EP EP17708341.7A patent/EP3419624B1/en active Active
- 2017-02-20 HU HUE17708341A patent/HUE053743T2/hu unknown
- 2017-02-20 ES ES17708341T patent/ES2862194T3/es active Active
- 2017-02-20 RU RU2018133158A patent/RU2737324C2/ru active
- 2017-02-20 EP EP21150907.0A patent/EP3842043A1/en not_active Withdrawn
- 2017-02-20 PL PL17708341T patent/PL3419624T3/pl unknown
- 2017-02-20 JP JP2018544147A patent/JP6941109B2/ja active Active
- 2017-02-20 US US16/078,431 patent/US11110083B2/en active Active
- 2017-02-20 CN CN201780012782.2A patent/CN108697703A/zh active Pending
- 2017-02-20 SI SI201730697T patent/SI3419624T1/sl unknown
- 2017-02-20 CA CA3014733A patent/CA3014733A1/en not_active Abandoned
- 2017-02-20 WO PCT/IB2017/050962 patent/WO2017145040A1/en active Application Filing
- 2017-02-20 AU AU2017223154A patent/AU2017223154B2/en not_active Ceased
- 2017-02-20 PT PT177083417T patent/PT3419624T/pt unknown
- 2017-02-20 DK DK17708341.7T patent/DK3419624T3/da active
- 2017-02-22 TW TW106105852A patent/TW201733583A/zh unknown
-
2018
- 2018-08-07 IL IL261036A patent/IL261036A/en unknown
-
2019
- 2019-01-02 HK HK19100007.0A patent/HK1257649A1/zh unknown
-
2021
- 2021-07-23 US US17/383,634 patent/US20210386729A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US11110083B2 (en) | 2021-09-07 |
| RU2737324C2 (ru) | 2020-11-27 |
| EP3419624A1 (en) | 2019-01-02 |
| RU2018133158A (ru) | 2020-03-24 |
| SI3419624T1 (sl) | 2021-05-31 |
| HK1257649A1 (zh) | 2019-10-25 |
| PL3419624T3 (pl) | 2021-08-02 |
| PT3419624T (pt) | 2021-04-07 |
| ES2862194T3 (es) | 2021-10-07 |
| TW201733583A (zh) | 2017-10-01 |
| EP3419624B1 (en) | 2021-01-13 |
| JP6941109B2 (ja) | 2021-09-29 |
| IL261036A (en) | 2018-10-31 |
| AU2017223154B2 (en) | 2019-08-15 |
| AU2017223154A1 (en) | 2018-08-30 |
| KR20180115700A (ko) | 2018-10-23 |
| RU2018133158A3 (da) | 2020-06-08 |
| HUE053743T2 (hu) | 2021-07-28 |
| WO2017145040A1 (en) | 2017-08-31 |
| EP3842043A1 (en) | 2021-06-30 |
| US20190083481A1 (en) | 2019-03-21 |
| CN108697703A (zh) | 2018-10-23 |
| CA3014733A1 (en) | 2017-08-31 |
| JP2019511476A (ja) | 2019-04-25 |
| US20210386729A1 (en) | 2021-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3419625T3 (da) | Fremgangsmåder til anvendelse af fxr-agonister | |
| DK3419624T3 (da) | Fremgangsmåder til anvendelse af fxr-agonister | |
| DK3368060T3 (da) | Glugacon-receptor-agonister | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
| DK3294700T3 (da) | Fremgangsmåde til fremstilling af limonen-4-ol | |
| DK3628732T3 (da) | Transposasesammensætninger til reduktion af insertionsbias | |
| DK3072835T3 (da) | Fremgangsmåde til fremføring | |
| HK1257648A1 (zh) | Fxr促效劑之使用方法 | |
| DK3512857T3 (da) | Spiro-bicykliske inhibitorer af menin-mll-interaktion | |
| DK3229995T3 (da) | Fremgangsmåde for fremstilling af et endestykke | |
| DK3529233T3 (da) | Fremgangsmåde til fremstilling af 3-alkylsulfanyl-2-chlor-n-(1-alkyl-1h-tetrazol-5-yl)-4-trifluoromethyl-benzamider | |
| DK3366832T3 (da) | Indretning til identifikation af stoftype | |
| DK3113675T3 (da) | Fremgangsmåde til overførsel af point-of-care-testdata | |
| DK3529262T3 (da) | Fremgangsmåder til fremme af t-cellerespons | |
| DK3117259T3 (da) | Vurdering af farvningskvalitet | |
| DK3166855T3 (da) | Fremgangsmåde for tilvejebringelse af foldelinjer | |
| DK3274143T3 (da) | Fremgangsmåde til fremstilling af lignocellulosematerialer | |
| DK3120153T3 (da) | Cellulær-baseret fremgangsmåde til bestemmelse af muligheden for defibrotid | |
| DK3507282T3 (da) | Fremgangsmåde til fremstilling af indolcarboxamidforbindelser | |
| DK3430072T3 (da) | Fremgangsmåde til oprensning af poloxamerer | |
| DK3265564T3 (da) | Fremgangsmåde til modulering af mecp2-ekspression | |
| DK3163041T3 (da) | Indretning til rensning af udstødning | |
| DK3148993T3 (da) | Fremgangsmåde til fremstilling af thiazolderivater | |
| DK3161136T3 (da) | Fremgangsmåde til berigelse af mikrovesikler |